Sign in

Lost your password?
(close)

Cancer

Celltrion Wins Big Deal for Breast Cancer Biosimilar in…

Celltrion Healthcare, the marketing arm of the biopharmaceutical company Celltrion won a huge deal in France last Friday (2nd November 2018) with big tenders for Herzuma, a biosimilar of Roche’s…

Bristol-Myers Squibb to Acquire Celgene to Expand its Cancer Portfolio

Last week, Bristol-Myers Squibb (BMS) announced that they have entered into a definitive merger agreement under…

Dying to Survive

This week, China has fast-tracked approval for 48 “much-needed medicines.” Regulators gave special…

Turkey: The Future of Cancer Care Uncertain

Turkey has one of the most revered Social Security Systems in the world, providing its citizens with…

Latest Report

In Conversation

Jin Hyoung Kang – President, Cancer Study Group, South Korea

Dr Jin Hyoung Kang, president of the Cancer Study Group comments on the scope for oncology drug development in Korea, and the issues resulting from the structure of Korea’s healthcare system. Dr Kang also offers his foresight in relation to the greater role AI and big data will play within the medical field.   We need to make a push…

Josep Tabernero – Director, VHIO; Head, Medical…

Anne W.M. Lee, Vice-Chair, HKACS, Hong Kong

Korean Research Team Develops Nanoparticle for Cancer Treatment

A Korean research team at Ulsan National Institute of Science and Technology (UNIST) have developed a cunning…

Related Report

Korean Research Team Develops Nanoparticle for Cancer Treatment

A Korean research team at Ulsan National Institute of Science and Technology (UNIST) have developed a cunning…

Novartis: EU approve gene-modifying cancer therapy

This week Novartis received approval from the European Commission (EC) for Kymriah, their chimeric antigen…

Korea’s Government-Funded Venture into Oncology

National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to…

UK charities: The funding giants of medical research

One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in…

Perspectives from J.P. Morgan’s 2019 Health Care Investor Conference

Our contributor at large, David Crean, Managing Director for Objective Capital Partners, attended J.P.…

Cancer Immunotherapy in Algeria: Between Therapeutic Progress and Budget…

Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, outlines the…

Euratom: Where Are We Now?

Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will &…

Peru: Better Cancer Survival Rates Than Europe or the US

Despite Peru’s sometimes-sluggish development when it comes to healthcare, the progression of cancer prevention…

We use cookies to ensure that we give you the best experience on our site. For more info click here